NU SKIN ENTERPRISES, INC. - 10-Q Summary (Q2 2024)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Nu Skin Enterprises, Inc. is a holding company developing and distributing premium beauty and wellness products under the Nu Skin, Pharmanex, and ageLOC brands. The company operates through nine segments: seven geographic Nu Skin segments (Americas, Mainland China, Southeast Asia/Pacific, Japan, South Korea, Europe & Africa, Hong Kong/Taiwan) and two Rhyz Investment segments (Manufacturing and Rhyz other).
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $439.1 million | $500.3 million | $856.4 million | $981.7 million |
| Gross Profit | $307.2 million | $364.7 million | $601.2 million | $712.6 million |
| Gross Margin | 70.0% | 72.9% | 70.2% | 72.6% |
| Operating Income (Loss) | $(125.6) million | $42.5 million | $(116.7) million | $58.6 million |
| Net Income (Loss) | $(118.3) million | $26.9 million | $(118.8) million | $38.3 million |
| Diluted EPS | $(2.38) | $0.54 | $(2.39) | $0.76 |
| Cash from Operations (YTD) | $54.5 million | $13.4 million | N/A | |
| Cash & Equivalents (End of Period) | $224.3 million | $235.6 million | ||
| Total Debt (Current + Long-term) | $458.3 million | $503.0 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 12% in Q2 and 13% YTD compared to the prior year. Core Nu Skin segments declined 17% in Q2, driven by macroeconomic pressures, reduced consumer spending, and declines in Customers (-14%), Paid Affiliates (-17%), and Sales Leaders (-16%).
- Impairment Charges: The company recorded $149.4 million in restructuring and impairment expenses in Q2 2024. This includes a $130.9 million non-cash goodwill impairment charge across multiple reporting units (Americas, Mainland China, Southeast Asia/Pacific, Japan, South Korea, Europe & Africa, Hong Kong/Taiwan, and BeautyBio) and a $10.1 million impairment of BeautyBio retail assets.
- Rhyz Growth: The Rhyz Investment segments grew 32% in Q2 and 43% YTD, partially offsetting declines in core Nu Skin segments. This growth is attributed to acquisitions (LifeDNA, BeautyBio) and organic growth.
- Expense Management: General and administrative expenses decreased by $19.1 million in Q2 due to restructuring efforts (labor and occupancy reductions). However, selling expenses as a percentage of revenue increased to 37.7% due to sales mix and incentives.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic for the remainder of 2024, citing upcoming global events (Nu Skin L!VE in Q3) and the launch of the new cognitive health brand, MYND360, in Q3.
- Restructuring: The company is executing a 2023 strategic plan with estimated total charges of ~$30.4 million ($22.2M cash, $8.2M non-cash). The program is expected to be substantially completed in the second half of 2024.
- Liquidity: The company maintains a $400 million term loan and a $500 million revolving credit facility. As of June 30, 2024, $90 million was drawn on the revolver. The company is in compliance with all debt covenants.
- Risks: Key risks include continued macroeconomic pressures in core markets (especially Mainland China and South Korea), foreign currency fluctuations (which negatively impacted revenue by 4.2% in Q2), and the potential for future impairment charges if market capitalization or forecasts decline further.
Investor Verification Checklist
- Impairment Triggers: Verify the specific assumptions used in the goodwill impairment analysis (discount rates, revenue growth forecasts) given the significant $130.9 million charge.
- China Exposure: Assess the sustainability of the Mainland China segment, which saw a 27% revenue decline and faces regulatory and economic headwinds.
- Rhyz Integration: Monitor the profitability trajectory of the Rhyz "other" segment (including BeautyBio), which currently reports negative contribution despite revenue growth.
- Debt Covenants: Confirm continued compliance with the consolidated leverage ratio (max 2.75:1) and interest coverage ratio (min 3.00:1) as operating income remains volatile.
- Dividend Sustainability: Review cash flow projections to ensure the $0.06 quarterly dividend remains sustainable given the current net loss position.